Chronic kidney disease (CKD) is an extremely serious health problem that causes poor health outcomes and substantial social and economic burdens worldwide. The high cardiovascular morbidity and mortality in the CKD population are mainly caused by extensive and progressive vascular calcification (VC). 1,2 Notably, in CKD patients, severe intimal calcification (known as atherosclerotic calcification and thought to originate from atherosclerosis) and medial calcification (known as Mönckeberg's sclerosis) are both prominent and can occur simultaneously, and both are accelerated with decreasing kidney function. 2,3 However, there are currently no effective treatment measures for VC. Although progress has been made in understanding the pathogenesis of VC, it is still largely assumptive and needs to be clarified. VC was previously regarded as a passive, degenerative disease. With further in-depth research, calcification has been found to be an active and adjustable process, analogous to bone formation, in